Sanofi : Une carte à jouer dans un marché à évangéliser
>Une efficacité démontrée, une sécurité d’emploi rassurante - Vendredi dernier, Sanofi a publié les résultats complets de son essai HERCULES évaluant tolebrutinib dans la sclérose en plaques secondairement progressive non active (nrSPMS) ainsi que GEMINI dans la forme rémittente de la pathologie (RMS). Nous connaissions déjà la teneur positive des résultats cliniques d’HERCULES sans pour autant en connaitre la spécificité. Concrètement, tolebrutinib retarde de 31% le ...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.